dibasic sodium phosphate in semaglutide Wegovy: Package Insert / Prescribing Information / MOA GLP1 Therapies​

A patient who is obese and diabetic may ultimately receive a different therapy than someone who is obese and hypertensive, or obese with rheumatoid arthritis, or obese with cognitive decline if we can design drugs that are turbo-charged to address these additional pharmacologies. Rounding up his presentation, DiMarchi encouraged the industry to also embrace observation

In naturally aged mouse models (1820 months old), daily oral administration of 5-amino-1mq capsules for 12 consecutive weeks significantly reduced NNMT activity and increased NAD+ levels in various tissues (liver, kidney, adipose tissue), along with markedly elevated expression of SIRT1 and SIRT3 proteins

But over the longer term, decreased adiposity, improved insulin sensitivity, and lower sympathetic drive from weight loss all contribute to sustained blood pressure improvements

semaglutide's SmPC advises stopping at least two months before planned conception

& Krause, K.-H